Supprelin La (Histrelin Acetate) Patent Expiration, LOE Window & CMS Spending

Supprelin La (Histrelin Acetate) by Endo Pharmaceuticals: FDA Orange Book LOE 2026-06-16, 0 AB generics, $18.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayN022058 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-06-16
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$18.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$18.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel